NASDAQ : TRIB
Trinity Biotech plc — Key statistics
Healthcare · Medical Devices · Ireland
Last price 6.63 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.39M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.09M |
| Enterprise Value | 137.94M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 22, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 813,132 |
| Shares Change (YoY) | +3.43% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 2.03% |
| Owned by Institutions (%) | 3.61% |
| Float | 673,756 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.12 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.25 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.75 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.72% |
| Return on Invested Capital (ROIC) | -57.55% |
| Return on Capital Employed (ROCE) | 26.48% |
| Weighted Average Cost of Capital (WACC) | 7.41% |
| Revenue Per Employee | $152,561 |
| Profits Per Employee | -$130,230 |
| Employee Count | 287 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.41 |
Taxes
| Measure | Value |
|---|
| Income Tax | 199,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.97 |
| 52-Week Price Change | -78.97% |
| 50-Day Moving Average | 7.69 |
| 200-Day Moving Average | 15.42 |
| Relative Strength Index (RSI) | 38.19 |
| Average Volume (20 Days) | 15,682 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 31,360 |
| Short Previous Month | 17,870 |
| Short % of Shares Out | 9.90% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 43.79M |
| Gross Profit | 16.89M |
| Operating Income | -9.55M |
| Pretax Income | -37.18M |
| Net Income | -37.38M |
| EBITDA | -8.24M |
| EBIT | -9.55M |
| Loss Per Share | -$60.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.14M |
| Total Debt | 137.98M |
| Net Cash | -132.85M |
| Net Cash Per Share | -$163.37 |
| Equity (Book Value) | -71.98M |
| Book Value Per Share | -115.42 |
| Working Capital | -105.31M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -5.93M |
| Capital Expenditures | -88,000 |
| Depreciation & Amortization | 1.30M |
| Net Borrowing | 11.81M |
| Free Cash Flow | -6.02M |
| FCF Per Share | -$7.40 |
Margins
| Measure | Value |
|---|
| Gross Margin | 38.57% |
| Operating Margin | -21.80% |
| Pretax Margin | -84.91% |
| Profit Margin | -85.36% |
| EBITDA Margin | -18.83% |
| EBIT Margin | -21.80% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.43% |
| Shareholder Yield | -3.43% |
| Earnings Yield | -964.26% |
| FCF Yield | -118.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -2.58 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |